Related Experiment Video
Updated: Oct 23, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma
Zhengzi Qian1, Leiyuan Chen2, Xinyuan Wang2
1Key Laboratory of Cancer Prevention and Therapy, Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is significantly upregulated in primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL). Elevated MALAT1 expression is linked to poorer survival outcomes, suggesting its potential as a prognostic biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is implicated in various cancer pathologies.
- The role of MALAT1 in primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) remains largely unexplored.
- Identifying novel prognostic markers is crucial for improving patient outcomes in PGI-DLBCL.
Purpose of the Study:
- To investigate the prognostic significance of MALAT1 expression in patients diagnosed with PGI-DLBCL.
- To determine if MALAT1 can serve as a predictive biomarker for patient survival in PGI-DLBCL.
Main Methods:
- Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to measure MALAT1 expression levels.
- The study included 90 patients with PGI-DLBCL, comparing tumor tissues with adjacent non-tumor tissues.
- Statistical analyses included ROC curve analysis, Kaplan-Meier survival analysis, and multivariate analysis.
Main Results:
- MALAT1 was significantly overexpressed in PGI-DLBCL tissues compared to non-tumor tissues (AUC = 0.838).
- Higher MALAT1 expression correlated with non-germinal center B-cell-like subtype, advanced stages (IIE-IV), and high IPI scores (3-5).
- Elevated MALAT1 levels were associated with inferior overall survival (OS) and progression-free survival (PFS) in PGI-DLBCL patients.
Conclusions:
- MALAT1 upregulation is a significant unfavorable prognostic factor in PGI-DLBCL.
- MALAT1 demonstrates potential as a novel prognostic biomarker for PGI-DLBCL.
- MALAT1 may represent a promising therapeutic target for PGI-DLBCL patients.
